Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Short Interest Up 13.2% in December

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) saw a large growth in short interest in December. As of December 31st, there was short interest totalling 1,720,000 shares, a growth of 13.2% from the December 15th total of 1,520,000 shares. Based on an average daily volume of 773,000 shares, the days-to-cover ratio is currently 2.2 days. Approximately 5.2% of the company’s stock are short sold.

Analysts Set New Price Targets

A number of research firms have recently issued reports on HOWL. HC Wainwright reissued a “buy” rating and set a $15.00 price objective on shares of Werewolf Therapeutics in a research report on Tuesday, November 19th. JMP Securities cut their price objective on shares of Werewolf Therapeutics from $12.00 to $4.00 and set a “market outperform” rating on the stock in a research report on Tuesday.

Werewolf Therapeutics Stock Down 0.7 %

NASDAQ HOWL traded down $0.01 during trading hours on Friday, hitting $1.33. The company’s stock had a trading volume of 179,090 shares, compared to its average volume of 273,803. Werewolf Therapeutics has a 52 week low of $1.31 and a 52 week high of $8.19. The company has a market capitalization of $59.27 million, a PE ratio of -0.87 and a beta of 0.38. The company has a current ratio of 10.10, a quick ratio of 10.10 and a debt-to-equity ratio of 0.29. The company’s 50-day simple moving average is $1.69 and its two-hundred day simple moving average is $2.09.

Hedge Funds Weigh In On Werewolf Therapeutics

Large investors have recently added to or reduced their stakes in the business. PFM Health Sciences LP lifted its position in shares of Werewolf Therapeutics by 4.9% during the 3rd quarter. PFM Health Sciences LP now owns 3,398,747 shares of the company’s stock worth $7,205,000 after buying an additional 157,673 shares in the last quarter. Millennium Management LLC lifted its position in shares of Werewolf Therapeutics by 96.4% during the 2nd quarter. Millennium Management LLC now owns 1,110,298 shares of the company’s stock worth $2,709,000 after buying an additional 544,881 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Werewolf Therapeutics by 6.3% during the 3rd quarter. Geode Capital Management LLC now owns 685,989 shares of the company’s stock worth $1,454,000 after buying an additional 40,692 shares in the last quarter. State Street Corp lifted its position in shares of Werewolf Therapeutics by 12.4% during the 3rd quarter. State Street Corp now owns 476,439 shares of the company’s stock worth $1,010,000 after buying an additional 52,528 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its position in shares of Werewolf Therapeutics by 103.1% during the 2nd quarter. Renaissance Technologies LLC now owns 171,000 shares of the company’s stock worth $417,000 after buying an additional 86,800 shares in the last quarter. Institutional investors own 64.84% of the company’s stock.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.